Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
To accelerate the development of T cell–based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day’s workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed — with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.